Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Top Cited Papers
Open Access
- 1 April 2009
- journal article
- review article
- Published by Taylor & Francis Ltd in International Journal of Nanomedicine
- Vol. 4, 99-105
- https://doi.org/10.2147/ijn.s3061
Abstract
Peer reviewed article authored by (Evelina Miele, Gian Paolo Spinelli, Ermanno Miele, Federica Tomao, Silverio Tomao). Read article or submit your manuscript for publishing.Keywords
This publication has 65 references indexed in Scilit:
- Immunotargeted Nanoshells for Integrated Cancer Imaging and TherapyNano Letters, 2005
- Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast CancerJournal of Clinical Oncology, 2003
- Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayerAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2003
- Biological applications of dendrimersCurrent Opinion in Chemical Biology, 2002
- Engineering Tumor-Targeted Gadolinium Hexanedione Nanoparticles for Potential Application in Neutron Capture TherapyBioconjugate Chemistry, 2002
- Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.2002
- Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding proteinAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2001
- Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulationEuropean Journal of Cancer, 2001
- The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targetingAdvances in Enzyme Regulation, 2001
- Role of Formulation Vehicles in Taxane PharmacologyInvestigational New Drugs, 2001